Epileptic Encephalopathy
Conditions
Brief summary
Study CL1-230815-001 (KANDLE) is a Phase Ib/II, First In Human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effect of S230815 in pediatric participants with KCNT1-related Developmental Epileptic Encephalopathy. To participate in the study, participants must have a diagnosis of Developmental Epileptic Encephalopathy due to a documented pathogenic or likely pathogenic variant in KCNT1 (to be confirmed by central genetic testing at the screening visit). The study consists of a screening period followed by two consecutive interventional parts. Part 1 will evaluate multiple ascending doses of S230815. Part 2 is a long-term treatment extension for participants who have completed Part 1. Participants will seamlessly roll-over from Part 1 to Part 2, resuming the same cohort as they were assigned in Part 1, and will receive S230815 for a maximum of 72 weeks.
Interventions
DRUGS230815- Starting dose A
Solution for injection
DRUGS230815- Dose B
Solution for injection
DRUGS230815- Dose C
Solution for injection
DRUGS230815- Dose D
Solution for injection
Sponsors
Institut de Recherches Internationales Servier
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Male or female pediatric participants aged 2-12 years old at screening, with a genetically confirmed diagnosis of Developmental Epileptic Encephalopathy (DEE) due to a pathogenic or likely pathogenic variant in KCNT1 confirmed by central genetic testing. * Stable dose of other regular medications and/or stable antiseizure interventions (such as ketogenic diet and vagal nerve stimulation).
Exclusion criteria
* Other clinical phenotypes associated with pathogenic or likely pathogenic variants in KCNT1 other than Epilepsy of Infancy with Migrating Focal Seizures or Early-Onset Epileptic Encephalopathy * Documented pathogenic or likely pathogenic variants in any other gene known to cause epilepsy identified through prior genetic testing. Variants of uncertain significance in other genes known to cause epilepsy may be considered on discussion with the sponsor. * Clinically significant medical history or clinical findings on physical examination, other than DEE, that in the judgment of the investigator, make the participant unsuitable for participation in the study and/or completion of the trial procedures, including, but not limited to: * Clinically significant prior or ongoing medical conditions within 30 days of the screening visit, as per investigator judgement. * Clinically significant abnormality on Electrocardiogram (ECG) at the screening visit, as per investigator judgement. * Clinically significant abnormality on laboratory testing at screening, including, but not limited to: * Renal insufficiency, which is defined as creatinine clearance \< 40 mL/min assessed as estimated glomerular filtration rate (eGFR) using Modification of Diet in Renal Disease (MDRD) formula * Hepatic derangement defined as transaminase values more than 3 times the Upper Limit of Normal (ULN) range, or total bilirubin values more than 1.5 times the ULN. * Positive hepatitis B surface antigen test, positive hepatitis C antibody test, positive for human immunodeficiency virus (HIV), as reported by a laboratory test within 6 months prior to the screening visit, or on screening bloods. * Bone, spine, bleeding disorders, or other disorder that exposes the participant to risk of injury or unsuccessful Lumbar puncture (e.g., haemophilia, Von Willebrand's disease, liver disease). * Contraindications to undergoing Magnetic Resonance Imaging (MRI), Lumbar puncture procedure and Intrathecal administration. * History of Central Nervous System (CNS) tumors or malignancies, including CNS metastatic disease. * Continuous respiratory support, defined as oxygen supplementation or non-invasive ventilation (e.g.: continuous positive airway pressure, bi-level intermittent positive airway pressure), required during waking hours. This does not include suctioning; cough assist devices or other devices that may be used regularly to clear airways. * Invasive ventilation including the presence of a tracheostomy. * Use of quinidine within 30 days prior to the screening visit. * Current use or anticipated use of antiplatelet or anticoagulant therapy during the study. * Current or past enrolment in an interventional clinical study in which an investigational therapy is/was administered within 30 days (or 5 half-lives of study agent, whichever is longer) prior to the screening visit. * Implantable CNS device that may interfere with the ability to administer the study drug via Lumbar puncture. * Known hypersensitivity to any oligonucleotide, as demonstrated by a systemic allergic reaction (e.g., changes in pulse, blood pressure, breathing function, etc.), or any other drug that in the opinion of the investigator may preclude study participation. * History of hydrocephalus requiring a ventriculoperitoneal shunt.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of Adverse Events (AE)'s. | Through End of study visit (A maximum of 116 weeks) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) parameters of S230815 in cerebrospinal fluid (CSF) Ctrough | Through week 96 | Ctrough is defined as the concentration reached immediately before the next dose is administered. |
| Pharmacokinetic (PK) parameters of S230815 in plasma AUC 0-τ | Through End of study visit (A maximum of 116 weeks) | Area Under the Curve (AUC) from dosing (time 0) to time t \[AUC0-t\] |
| Pharmacokinetic (PK) parameters of S230815 in plasma Cmax | Through End of study visit (A maximum of 116 weeks) | Cmax is defined as the maximum (peak) observed concentration following a dose. Measured 0.5, 2, 4, 8 , and 24 hours post dose |
| Pharmacokinetic (PK) parameters of S230815 in plasma Ctrough | Through End of study visit (A maximum of 116 weeks) | — |
| Relative change from baseline in seizure frequency as recorded by daily seizure logs | Through End of study visit (A maximum of 116 weeks) | — |
| Relative change from baseline in seizure frequency as recorded by periodic 24h Video Electroencephalogram (vEEG) assessment | Through End of study visit (A maximum of 116 weeks) | — |
| Number and administration frequency of rescue medication | Through End of study visit (A maximum of 116 weeks) | — |
Countries
France, Italy, Japan, Spain, United States
Contacts
CONTACTInstitut de Recherches Internationales Servier
Outcome results
None listed